Results 231 to 240 of about 27,271 (263)

Differentiated Thyroid Cancer Is Associated With Sex-specific Immune Response. [PDF]

open access: yesJ Endocr Soc
Shobab L   +14 more
europepmc   +1 more source

Multidimensional plasticity of natural killer cells in tumours. [PDF]

open access: yesCell Death Dis
Yang X, Song Z, Chen L, Jia Q, Li M.
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

TIGIT-Fc Promotes Antitumor Immunity

Cancer Immunology Research, 2021
Abstract T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a checkpoint receptor that mediates both T-cell and natural killer (NK)–cell exhaustion in tumors. An Fc-TIGIT fusion protein was shown to induce an immune-tolerance effect in a previous report, but the relevance of the TIGIT ...
Xian, Shen   +7 more
openaire   +2 more sources

TIGIT limits immune pathology during viral infections [PDF]

open access: yesNature Communications, 2020
AbstractCo-inhibitory pathways have a fundamental function in regulating T cell responses and control the balance between promoting efficient effector functions and restricting immune pathology. The TIGIT pathway has been implicated in promoting T cell dysfunction in chronic viral infection.
Michelle Schorer   +2 more
exaly   +7 more sources

Abstract 5421: Prediction of intratumoral TIGIT receptor occupancy after the treatment with anti-TIGIT antibodies

Cancer Research, 2022
Abstract Background: T-cell immunoreceptor with immunoglobulin and tyrosine based inhibitory motif domain (TIGIT) is a co-inhibitory immune checkpoint receptor expressed on several types of immune cells, which can suppress T-cell activation, promote T-cell exhaustion, and suppress natural killer cell mediated cytotoxicity.
Dmitry Shchelokov   +7 more
openaire   +1 more source

Tiragolumab Results Cast Shadow on TIGIT Pipeline

Cancer Discovery, 2022
Abstract Genentech's TIGIT-targeted antibody tiragolumab missed its endpoints in two late-stage lung cancer trials, raising doubts about one of the most widely studied next-generation checkpoint targets in immuno-oncology. But numerical signs of benefit among certain patients with metastatic non–small cell lung cancer suggest that TIGIT ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy